HOME >> MEDICINE >> NEWS
New research shows major sleep disturbances overlooked in management of patients with Parkinson's disease

Once Daily Cabergoline Successfully Controls Sleep Disturbances

Up to 96 percent of patients with Parkinson's disease (PD) experience serious sleep disturbances caused by many factors,1 however, these symptoms are often overlooked by doctors. As a consequence many patients suffer from excessive daytime sleepiness, impaired cognitive ability and an overall diminished quality of life, warned researchers presenting at the International Congress of the European Federation of Neurological Societies (14th-18th October, 2000; Copenhagen).

To improve PD management, researchers presented encouraging findings on new ways of monitoring PD symptoms, including sleep disturbance and motor problems. In two separate presentations, researchers presented data using a newly designed Parkinson's Disease Sleep Scale (PDSS), a patient-administered questionnaire which could help clinicians diagnose nocturnal disability quickly and provide a useful tool to monitor response to treatment. Actigrapy, the second test discussed, measures limb motor activity and circadian variations by use of a special device called an Actigraph. Using both testing methods, investigators evaluated the efficacy of the long-acting dopamine agonist cabergoline (CABASER/CABASERIL tablets) on sleep disturbances in PD patients and found cabergoline offers important benefits, possibly due to its long duration of action, in achieving significant improvement of the symptoms underlying PD during the night as well as the day.

Dr K. Ray Chaudhuri, Consultant and Honorary Senior Lecturer at Kings College Hospital, London, explained that current methods lack quantitative aspects, thereby making them inadequate for the precise assessment of symptoms and treatment. The most commonly employed sleep questionnaire that is traditionally used in clinical practice is the Epworth Sleepiness Scale (ESS). Although motor disturbances are an important cause of sleep disturbance, the ESS scale o
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-207-465-8752
Ketchum
24-Oct-2000


Page: 1 2 3 4

Related medicine news :

1. Public morally obliged to take part in scientific research, says leading ethicist
2. U of M researcher says Viagra may cause permanent vision loss in some men
3. Indiana University researchers closer to helping hearing-impaired using stem cells
4. Can you read my mind? W.M. Keck Foundation funds innovative brain research at Carnegie Mellon
5. RIT takes eye-tracking research to next level
6. UW research shows risk factors for relapse among health care professionals who abuse drugs
7. Protein that helps skin cancer spread identified by Stanford researchers
8. US life expectancy about to decline, researchers say
9. Ethical discussion should come before research
10. Philanthropist Paul F. Glenn launches labs for aging research at Harvard Medical School
11. Gene for age-related macular degeneration discovered by Yale researchers

Post Your Comments:
(Date:3/6/2015)... Protein identification is increasingly being ... science research including drug discovery, diagnostics, immunology and ... was valued at $1,569.00 million in 2014 and ... 10.63% to reach $2,600.28 million in 2019. , ... protein based on protein size, shape, sequence and ...
(Date:3/6/2015)... As healthcare providers create one ... from disparate systems, they are using OnBase by ... efficiency. Enterprise content management (ECM) solutions ... IT solutions, including electronic medical records (EMR), enterprise ... , The following organizations have recently integrated ...
(Date:3/6/2015)... March 06, 2015 Saving Moses, a ... the world is traveling to Angola, Africa March 7-14 ... their malnutrition program. , This will be the organizations ... Angola, demonstrating their commitment to the region’s population by ... team will engage with the mothers and babies of ...
(Date:3/6/2015)... 06, 2015 Follow us on ... pharmacokinetics of a drug refers to testing of absorption, ... an organism. When toxicity studies are clubbed together with ... ADME/Tox. Increasing focus on lowering costs and time during ... worldwide. The traditional drug development model uses toxicity and ...
(Date:3/6/2015)... March 06, 2015 “On Tap” takes the ... the grand stage, to the silver screen and to modern ... precision toe-tapping numbers and their famous eye-high kicks! Producers, directors ... rich history of tap dancing in this robust show, showcasing ... of the United States. , “On Tap” is proud ...
Breaking Medicine News(10 mins):Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 2Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 3Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 2Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 3Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
(Date:3/6/2015)... , March 6, 2015  Palatin Technologies, Inc. (NYSE MKT: ... 27 th Annual ROTH Conference on Wednesday, March 11, ... held at the Ritz Carlton Laguna Niguel in ... Spana , Ph.D., President and Chief Executive Officer of Palatin ... programs. About Palatin Technologies, Inc. ...
(Date:3/6/2015)... , March 6, 2015   Hospira, Inc. ... Food and Drug Administration (FDA) on today,s FDA approval of ... . This is a watershed moment for improving patient access ... leading global provider of biosimilars, Hospira has seen first-hand the ... a proud participant in these early stages of the development ...
(Date:3/6/2015)... March 6, 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the ... diseases and cancer, today announced that James A. ... present a corporate overview at the 27th Annual ROTH ... time.  Aethlon was previously scheduled to present at 5:30 ... will be held at The Ritz-Carlton Hotel in ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
Cached News: